PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. Jun 5, 2012; 78(23): 1824–1831.
PMCID: PMC3369520
Multicenter validation of a bedside antisaccade task as a measure of executive function
J. Hellmuth, MD, MHS,*
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
J. Mirsky, MA,*
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
H.W. Heuer, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
A. Matlin, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
A. Jafari, BA,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
S. Garbutt, PhD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • Alcon Laboratories, Clinical Site Manager
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
M. Widmeyer, BA,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
A. Berhel, BA,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NIH, contract # HHSN271200623661C, research coordinator, 4 years
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
L. Sinha, BA,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • NONE
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • NONE
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
B.L. Miller, MD,
Scientific Advisory Boards:
  • 1. Alzheimer’s Disease Clinical Study (DSMB)
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • 1. Neurocase, Editor, 2003- 2. ADAD, Associate Editor, 2009
Patents:
  • NONE
Publishing Royalties:
  • Behavioral Neurology of Dementia, Cambridge 2009 Handbook of Neurology, Elsevier 2009 The Human Frontal Lobes, Guilford, 2008
Employment, Commercial Entity:
  • NONE
Consultancies:
  • 1. Allon Pharmaceutircals 2. Novartis 3. TauRx
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • Novartis
Research Support, Government Entities:
  • 1. NIA P50 AG23501 PI, (2004-) 2. NIA P01 AG19724 PI, (2002-) 3. State of California Alzheimer’s Center PI (1999-)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
J.H. Kramer, PsyD,
Scientific Advisory Boards:
  • NONE
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • California Verbal Learning Test, Pearson, Inc. 2001
Employment, Commercial Entity:
  • NONE
Consultancies:
  • NONE
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • NONE
Research Support, Government Entities:
  • 5 R01 AG022983-06 Kramer (PI)09/01/04 – 07/31/15 Attention and Executive Functioning in FTD The overall goal of this project is to define the characteristics and neuroanatomical predictors of attention and executive impairment in FTD. Role: PI HHS99271200623661C Kramer (PI) 12/31/2005 – 12/30/2011 Domain Specific Tasks of Executive Function The objective of this contract is to develop psychometrically robust Executive Function (EF) measurement tools that are accepted by the neurology clinical trials and clinical research communities. Role: PI 03-75271 Miller (PI) 07-01-2006 / 06-30-2012 Multidisciplinary Research Program to Improve the Differential Diagnosis of Dementia This is a clinical center that provides diagnosis and care to patients with dementia. It has been renewed as one of the Alzheimer’s Research Centers of California (ARCC) that will, in addition to performing patient care, undertake transitional research. Role: Co-Investigator 5 P01AG019724-05 Miller (PI) 09-01-2002 / 08-31-2012 Frontotemporal Dementia: Genes, Images and Emotions, Clinical Core The goal is to determine the genetic, imaging, and emotional and diagnostic features of fontotemporal lobar degeneration. Role: Co-Investigator 3 P50 AG23501 Miller (PI) 04-01-2004 / 03-31-2014 New Approaches to Dementia Heterogeneity: Alzheimer’s Disease Research Centers, Core B The main goal of this project is to integrate science and clinical resources to investigate Alzheimer’s disease (AD), non- AD dementias, and mild cognitive impairment. Role: Co-Investigator 2002/2I Miller (PI) 1-01-2007 /12-31-2011 A Hillblom Network Program for the Pre-clinical Identification of Alzheimer’s Diseases and Other Age-related Dementias The overlying goal of this program is to develop successful strategies for diagnosing and then slowing or preventing the progression from healthy aging or mild cognitive impairment (MCI) to dementia. Role: Co-Investigator 1 R01 AG025303-01A1 Rugo/Jagust (PI) 02/01/2007 – 06/30/2011 Effects of Chemotherapy on Brain Function Breast cancer is the most common form of cancer in women. An increasing emphasis on early detection, along with more effective treatments, has resulted in increased survival rates. While it is recognized that chemotherapy can cause cognitive impairment, often termed "Chemobrain", most of the studies done to date have limitations and few have focused on underlying brain mechanisms. Role: Co-Investigator 07-65807 Kramer (PI) 01/01/2008-12/31/2011 New Diagnostic Criteria for Frontotemporal Lobar Degeneration The purpose of this three-year consortium application is to test the reliability and validity of new criteria and develop training modules that will efficiently translate improved diagnostic methods to other state ARCCs and to community health care providers. Role: PI 2 P01 AG012435-09 Chu (PI) 06-01-2008 / 05-31-2013 Aging Brain-Vasculature, Ischemia and Behavior, Central Coordinating Core A The overall goal of the UCSF section of the core is subject recruitment and follows up evaluations of subjects with cerebrovascular disease CVD and interactions with AD. Role: UCSF PI 1 R01 AG032289 Kramer (PI) 12/01/2009 – 11/30/2014 Mechanisms of Executive Decline in Normal Aging The goal of this project is to identify the cognitive mechanisms and neural structures that underlie the decline in executive functioning observed in aging using high field MRI and cognitive measures. Role: PI
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • NONE
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
and A.L. Boxer, MD, PhDcorresponding author
Scientific Advisory Boards:
  • I have served on Medical Advisory Boards for: Accera, Bristol-Myers Squibb, Genentech, Medivation, Plexxikon, TauRx and Phloronol.
Gifts:
  • NONE
Funding for Travel or Speaker Honoraria:
  • NONE
Editorial Boards:
  • NONE
Patents:
  • NONE
Publishing Royalties:
  • The Disinhibited Brain: A Portrait of Frontotemporal Dementia. Discover Magazine Presents the Brain. 2010
Employment, Commercial Entity:
  • NONE
Consultancies:
  • Bristol Myers Squibb, EnVivo, Genentech, Phloronol, Plexxikon, Registrat-Mapi and TauRx
Speakers’ Bureaus:
  • NONE
Other Activities:
  • NONE
Clinical Procedures or Imaging Studies:
  • NONE
Research Support, Commercial Entities:
  • I received research support from Allon, Avid, BMS, Elan, Forest,Genentech, Janssen, Medivation, Novartis, and Pfizer for conducting clinical trials
Research Support, Government Entities:
  • NIH: R01AG031278 (PI), R01AG038791 (PI), R01AG032306 (co-I), R01AG022983 (Co-I)
Research Support, Academic Entities:
  • NONE
Research Support, Foundations and Societies:
  • Alzheimer’s Drug Discovery Foundation, Association for Frontotemporal Dementias, CurePSP, Hellman Family Foundation, John Douglas French Foundation, Silicon Valley Foundation and the Tau Research Consortium
Stock/Stock Options/Board of Directors Compensation:
  • NONE
License Fee Payments, Technology or Inventions:
  • NONE
Royalty Payments, Technology or Inventions:
  • NONE
Stock/Stock Options, Research Sponsor:
  • NONE
Stock/Stock Options, Medical Equipment & Materials:
  • NONE
Legal Proceedings:
  • NONE
From the Department of Neurology, Memory and Aging Center, University of California, San Francisco.
corresponding authorCorresponding author.
*These authors contributed equally to this work.
Study funding: Supported by the NIH (R01AG038791, HHSN271200623661C, R01AG031278, P50AG023501, P01AG019724), the John Douglas French Foundation, the Hellman Family Foundation, the Larry L. Hillblom Foundation, and the Tau Research Consortium.
Correspondence & reprint requests to Dr. Boxer: aboxer/at/memory.ucsf.edu
Received June 22, 2011; Accepted September 13, 2011.
Objective:
To create and validate a simple, standardized version of the antisaccade (AS) task that requires no specialized equipment for use as a measure of executive function in multicenter clinical studies.
Methods:
The bedside AS (BAS) task consisted of 40 pseudorandomized AS trials presented on a laptop computer. BAS performance was compared with AS performance measured using an infrared eye tracker in normal elders (NE) and individuals with mild cognitive impairment (MCI) or dementia (n = 33). The neuropsychological domain specificity of the BAS was then determined in a cohort of NE, MCI, and dementia (n = 103) at UCSF, and the BAS was validated as a measure of executive function in a 6-center cohort (n = 397) of normal adults and patients with a variety of brain diseases.
Results:
Performance on the BAS and laboratory AS task was strongly correlated and BAS performance was most strongly associated with neuropsychological measures of executive function. Even after controlling for disease severity and processing speed, BAS performance was associated with multiple assessments of executive function, most strongly the informant-based Frontal Systems Behavior Scale.
Conclusions:
The BAS is a simple, valid measure of executive function in aging and neurologic disease.
The ability to inhibit prepotent or reflexive impulses and biological drives is an important function of the frontal lobes and is impaired in a variety of brain diseases.1 A commonly used measure of cognitive inhibition is the antisaccade (AS) task, which requires suppression of a visually guided saccade toward a target and generation of voluntary saccade in the opposite direction.2,3 The percentage of correct AS responses is sensitive to frontal lobe dysfunction in aging,4 schizophrenia,58 Huntington disease (HD),9,10 and a variety of neurodegenerative dementias.1113
Despite the potential clinical utility of the AS task in evaluating neurologic function, current methods of evaluation are limited to informal bedside evaluation or the use of expensive eye-tracking equipment.14 Bedside AS evaluation as part of a clinical neurologic examination makes quantification difficult and does not include accurately controlled stimulus presentation, limiting its use in scientific studies. Oculographic equipment necessitates significant financial resources and expertise and limits assessments to specialized laboratories.
A simple, inexpensive, and well-validated bedside AS (BAS) task requiring only a standard laptop computer would be a useful clinical tool to identify and monitor the progression of disorders involving frontal-subcortical and executive dysfunction.15 The goals of this study were therefore to 1) validate the BAS relative to AS measured using an infrared eye tracker, 2) determine whether the BAS is more sensitive to neuropsychological measurements of executive function as compared to other neuropsychological domains, and 3) validate the BAS relative to real-world assessments of executive function in a multicenter study.
Subjects.
UCSF.
A total of 103 subjects were evaluated at the University of California, San Francisco (UCSF) Memory and Aging Center. Subjects received a neurologic examination and neuropsychological testing within 6 months of BAS testing. Subjects were classified as follows: cognitively normal elder (NE), Alzheimer disease (AD), frontotemporal dementia (FTD), mild cognitive impairment (MCI), or progressive supranuclear palsy (PSP). NE subjects had no neurologic complaints, normal neurologic and neuropsychological examinations, and Clinical Dementia Rating (CDR)16 scores of 0. Individuals with MCI had a memory or other cognitive complaint corroborated by an informant (CDR ≥ 0.5). Subjects with AD met National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD17; subjects with FTD met the Neary criteria for frontotemporal dementia, semantic dementia, or progressive nonfluent aphasia18; and subjects with PSP met National Institute of Neurological Disorders and Stroke Society for Progressive Supranuclear Palsy criteria for probable PSP.19 Three patients were diagnosed with corticobasal syndrome20 and included in the FTD group. A subset of subjects (14 NE, 6 AD, 8 frontotemporal lobar degeneration, 2 MCI, and 3 PSP subjects) received AS evaluation on a laboratory infrared eye tracker.
Multicenter.
To assess the validity of the BAS as a measure of executive function in a multicenter study, 6 sites (Mayo Clinic, Rochester; UC Berkeley; UC Davis; UCSF; University of Iowa; and University of Texas Southwestern) assessed 397 adults (mean age 58.4, range 18–91) according to standard procedures and diagnosed subjects as either cognitively normal or as having a neurologic disease (table e-1 on the Neurology® Web site at www.neurology.org). The data were acquired as part of a multicenter validation study of a novel, National Institute of Neurological Disorders and Stroke–funded, executive function battery, entitled Executive Abilities: Methods and Instruments for Neurobehavioral Evaluation and Research (EXAMINER; http://examiner.ucsf.edu/index.htm) that included the BAS. The cohort included individuals with MCI and dementia, as listed above, as well as patients with frontal and nonfrontal focal brain lesions. Patients with Huntington disease (HD) were symptomatic gene carriers, patients with multiple sclerosis (MS) met McDonald criteria,21 patients with Parkinson disease (PD) met Albanese criteria,22 and patients with traumatic brain injury (TBI) had a history of moderate to severe injury (Glasgow Coma Scale <12 at time of injury). BAS data were not collected on 32 out of 429 subjects (7.4%) from the EXAMINER study due to factors related to subjects' physical or mental capacity.
Standard protocol approvals, registrations, and patient consents.
All procedures were approved by the UCSF or local institutional review board. Written informed consent was obtained from all subjects or from a surrogate if cognitive impairment prevented individuals with dementia from providing informed consent.
Neuropsychological testing.
At UCSF, general intellectual function was assessed using the Mini-Mental State Examination (MMSE).23 Memory was assessed with a 10-minute recall of the Benson figure. Visuospatial abilities were tested by copying the same Benson figure, the Number Location condition from the Visual Object Spatial Perception (VOSP) battery,24 and the Face Matching and Affect Matching conditions of the Comprehensive Affect Testing System (CATS). Language skill was evaluated by a 15-item Boston Naming Test (BNT),25 phonemic fluency (number of D- or H-words in 1 minute), and category fluency (number of animals in 1 minute). Neuropsychological tests of executive function assessed set-shifting (time to make all correct lines in a modified trail-making test),26 inhibition (the Stroop interference condition),26 generation (design fluency subtest from the Delis-Kaplan Executive Function System; filled dots condition, number correct),27 and working memory (longest correct backward digit span),28 as well as the ability to perform 5 arithmetic calculations and interpret 3 similarities and 3 proverbs (abstraction).
Neuropsychological performance was assessed as part of the EXAMINER battery in the multicenter cohort. Tests included the Digit Symbol Subscale (number of correct responses),28 Flanker task,29 Stroop Interference (number correct),26 1-back task (number correct), Continuous Performance Task (Go/NoGo task; number correct), verbal fluency (number of correct F- and l-words in 1 minute), category fluency (number of correct animals and vegetables in 1 minute), and generation (design fluency subtest from the Delis-Kaplan Executive Function System; empty and switching dots condition, scaled scores).27 Social abilities were assessed using the Revised Self-Monitoring Scale (RSMS),30 a Social Norms questionnaire (total correct), and The Awareness of Social Inference Test (total score).31 Behavioral features were categorized by the examiner using a 9-item Behavioral Rating Scale. The informant components of the Frontal Systems Behavior Scale (FrSBe)32 were also administered.
Bedside saccade tasks.
Prosaccade (PS) and AS tasks were used to measure oculomotor responses and response inhibition, respectively. Stimuli for both PS and AS tasks were presented on a 15-inch laptop computer screen using E-Prime software (version 2.0, Psychology Software Tools Inc., Pittsburgh, PA; software available from authors upon request). Subjects were seated approximately 80 cm from the eye level laptop screen and the rater was positioned behind the laptop screen in clear view of the subjects' eye movements (figure e-1). Raters were provided a script that instructed the subjects to “look at the opposite direction of where the dot moves” for the AS trials. Raters were instructed to record the direction of only the first eye movement after the stimulus and not any subsequent self-corrected errors (see below; e-Instructions).
Prosaccade control condition.
In the PS trials, a white dot appeared on a black background for 1,000 msec, followed by a 200 msec gap prior to appearance of a left or right stimulus dot at 10 degrees horizontal for 900 msec. A blank screen appeared between trials for a randomized 1,000–4,000 msec intertrial interval (ITI).
Bedside antisaccades.
Stimuli for the AS trials were similar to the PS trials. However, the AS trials included a 1,000 msec white central dash following the center fixation dot to remind the subjects that an AS was to be performed. The lateral target appeared for 1,000 msec, followed by a randomized, 1,000–2,000 msec ITI.
Testing began with 1 block of 10 PS trials, followed by 1 practice AS trial, and then a series of 40 AS trials, divided into 2 blocks of 20. Raters documented the direction of the subject's initial eye movements for each trial on a provided scoring sheet. An auditory marker (a recorded number) of the trial number accompanied each center fixation to ensure correct recording of subjects' responses. Since the trials were presented in pseudorandom order, the normative eye deviation (R or L) responses could be indicated on the scoring sheet, allowing raters to calculate the percentage of correct responses for the AS trials ([number of correct responses/40] × 100).
Laboratory eye movement recordings.
The movements of the right eye were measured at UCSF in a darkened laboratory using a Dual Purkinje Image Eye Tracker (Fourward Technologies Generation 6.1, Buena Vista, VA) as described in our previous work.13 Responses to at least 10 AS trials were recorded in each direction, and only subjects with at least 20 high-quality trials were entered into the analysis. Self-corrected error responses consisted of a correct AS response (away from the target) within 500 msec after an initial erroneous PS (toward the target). The interval between bedside and laboratory AS testing was a maximum of 6 months.
Data analysis.
Mean group differences for demographics, BAS performance, dementia severity, and neuropsychological performance were determined using analyses of variance with post hoc Tukey tests; a χ2 test was used for comparing gender frequency. BAS performance was correlated with laboratory AS performance, MMSE, Clinical Dementia Rating–sum of boxes (CDR-SB), and education using Pearson correlations. Partial correlations controlling for education and CDR-SB were used to evaluate the relationships between bedside AS performance and neuropsychological measures. For the multicenter analyses, 3 models were created for comparison of BAS performance with patient, examiner, and informant measures: model 1: Pearson correlation; model 2: partial correlation controlling for age and education; and model 3: partial correlation controlling for age, education, and Digit Symbol number correct. In models 2 and 3, Flanker Incongruent median reaction time was also controlled for by Flanker Congruent median reaction time and Stroop Interference scores were also controlled for by Stroop Color Naming scores (number correct). Corrections for multiple comparisons were implemented using the Bonferroni procedure for each hypothesis. For the UCSF cohort, separate corrections were calculated for the Pearson correlation on general items (MMSE, CDR-SB, and education; n = 3) and for the partial correlation of nonexecutive (n = 8) and executive (n = 6) neuropsychological tasks. For the multicenter cohort, separate Bonferroni corrections were calculated for models 1, 2, and 3 based on the number of observations in each (n = 19, 17, and 16, respectively). All statistical analyses were performed using PASW for Windows (version 18.0, SPSS, Chicago, IL).
We first validated BAS performance by comparing the percentage of correct responses measured at the bedside using our novel laptop stimuli with performance in the laboratory using an infrared eye tracker. The percentage of correct BAS responses correlated with the percentage of correct AS responses measured using the infrared eye tracker (r = 0.862, p < 0.001; n = 33; figure 1). In addition, correct BAS responses also correlated with the percentage of correct AS plus self-corrected error responses (r = 0.667, p < 0.001).
Figure 1
Figure 1
Bedside antisaccade (AS) performance as a function of laboratory eye movement measurements
To determine whether the BAS is more sensitive to executive function than other neuropsychological domains, BAS performance was correlated with performance on a standard neuropsychological battery in our UCSF cohort (n = 103; table 1). The percentage of correct AS responses on the BAS correlated with MMSE (r = 0.423) and CDR-SB (r = −0.605; p < 0.05, Bonferroni corrected for both) but not education (r = 0.221). Since BAS performance strongly correlated with a general measure of disease severity (CDR-SB) and cognition (MMSE), and educational attainment might affect the degree of impairment on BAS, we controlled for disease severity and education in subsequent analyses to determine neuropsychological domain specificity. After controlling for CDR-SB and education, BAS performance correlated most strongly with neuropsychological tests of executive functioning, including time to complete modified Trails, digits backward, Stroop inhibition, and design fluency (p < 0.01, Bonferroni corrected for all; table 2). BAS performance was also correlated with CATS Facial Matching (p < 0.01), letter fluency (p < 0.05), and category fluency (p < 0.01, Bonferroni corrected for all).
Table 1
Table 1
Demographics and performance on bedside antisaccade taska
Table 2
Table 2
Correlation of cognitive testing with bedside antisaccade performance
The validity of the BAS as a measure of executive function was investigated using data from a multicenter study of a novel executive function battery (EXAMINER). BAS performance was measured in adults (ages 18 to 91) who were cognitively normal or diagnosed with AD, focal brain lesions, FTD, HD, MCI, MS, PD, PSP, or TBI (table e-1) at 6 performance sites and compared with direct, examiner-based, and informant-based measures of executive function. BAS performance did not correlate with age or education. In bivariate Pearson correlations, all EXAMINER measures correlated with BAS performance (model 1, table 3; p < 0.05, Bonferroni corrected for all). After controlling for age and education (model 2), BAS performance correlated with all EXAMINER measures except for Flanker Incongruent median reaction time (p < 0.05, Bonferroni corrected for all). When controlling for age, education, and processing speed (Digit Symbol Number; model 3), BAS performance remained correlated with all measures except for Flanker Incongruent median reaction time and RSMS total (p < 0.05, Bonferroni corrected for all). Of all EXAMINER measures, BAS performance was most strongly associated with informant-based measures of executive function from the FrSBe scale.
Table 3
Table 3
Correlation of bedside antisaccade performance with EXAMINER measures
This study describes a novel BAS task that requires no specialized equipment. We demonstrate that the BAS is strongly correlated with oculographically measured AS performance, indicating that BAS can be related to the extensive literature on the AS task in neurologic and psychiatric disease, as well as mechanistic studies of the AS task in both humans and nonhuman primates. In a cohort of cognitively normal participants and patients with neurodegenerative disease, BAS performance correlated more strongly with measures of executive function than memory, language, or visuospatial skill (after controlling for disease severity and education), similar to previous reports of oculographically measured AS performance.12 In a multicenter study, BAS performance was associated with both neuropsychological and informant-based measures of executive function in normal adults and individuals with a variety of neurologic disorders. Together, our results suggest the BAS is a cost-effective tool that can be used to assess both executive motor function and disease severity in a variety of neurologic disorders.
We found that subjects with a variety of dementia diagnoses exhibited an impaired ability to inhibit reflexive PS responses on the BAS. The similarity between this finding and previous results using an infrared eye tracker,1113,33 along with the strong correlation of performance on the BAS and our laboratory AS task, further underscores the validity of the task. Impaired AS performance is correlated with structural alterations to the right greater than left premotor regions of the frontal lobes in focal lesion patients,34 neurodegenerative disease,12 psychiatric illness,35 and normal aging.4,36 Our results suggest that the BAS may be sensitive to damage to these same brain regions and could be used as a screen for such damage at the bedside.
The same frontoparietal network necessary for AS performance has been previously implicated in executive control in normal aging,4 schizophrenia,57,37 and neurodegenerative disease.1213 The observed correlation between BAS performance and neuropsychological measures of executive function further supports our hypothesis that BAS relies on the integrity of the same network as other AS paradigms. Because the correlations were strongest between BAS performance and executive function tasks that require greater motor skill in the form of drawing lines (Modified Trails and Design Fluency), it is possible that the BAS is more sensitive to executive motor control tasks as opposed to executive function as a whole. More work will be needed to confirm this hypothesis.
In our multicenter cohort, we also found that BAS performance strongly correlated with several measures of executive function, behavior, social cognition, and an informant measure of executive function: the FrSBe, a reliable measure of damage to the frontal lobes32 that produces a total score as well as subscales for Apathy, Disinhibition, and Executive Dysfunction. Even after controlling for demographics and processing speed, BAS performance was correlated with all 4 informant FrSBe-based scores. The FrSBe is sensitive to frontal lobe function in a variety of neurologic disorders including focal lesions, AD, Parkinson disease, and ALS. Our results suggest that the BAS may be useful in efficiently quantifying frontal lobe dysfunction in individuals for whom no informant is available.
BAS performance was also correlated with disease severity, as measured by MMSE and CDR-SB, in the UCSF cohort. Unlike a previously described bedside AS task,14 we did not observe a correlation between BAS performance and a test of memory. This finding is likely explained by the more diverse population of neurodegenerative disease subjects in our study and the fact that we controlled for disease severity (CDR-SB) in our analyses. Had we limited our analysis to MCI and AD subjects and not corrected for CDR-SB, our results would have been similar to the previous study (data not shown). Interestingly, BAS performance was different in MCI and dementia. Patients with AD, frontotemporal lobar degeneration, and PSP made more BAS errors than patients with MCI. Since we are unaware of any previously published reports of AS performance measured in MCI, further studies will be necessary to interpret the significance of these findings.
Subjects performed better on the bedside version of the AS task than the laboratory version. Several factors may contribute to this finding, including rater errors and time delay between testing modalities. A likely contributor is the presence of ambient lighting and other visual stimuli in the BAS condition that might partially counteract the effects of the gap stimulus, which increases error rate as a result of an increase in express saccade generation in the absence of fixation stimuli.1 In this respect, our findings are similar to those reported for a previous BAS task.14 Of note, our BAS task includes auditory cues to improve raters' data acquisition, which might also influence task performance.38,39
A limitation of the study was that we did not measure the interrater or intrarater reliability of the BAS. This will be necessary in the future for the BAS to be used in multicenter studies such as clinical trials, although the AS task has been used to measure disease progression in HD15 and genetic risk in first-degree relatives of patients with schizophrenia in large, multicenter studies.40 Such reliability studies are currently under way.
Our findings indicate the BAS is a valid measure of executive motor control in aging and neurologic disease, offering practitioners a rapid, simple clinical tool to evaluate executive functioning and dementia severity in their patients.
Supplementary Material
Data Supplement
Accompanying Editorial
ACKNOWLEDGMENT
The authors thank John Neuhaus, PhD, for statistical advice, and Drs. Robert Knight, Daniel Tranel, Glenn Smith, Dan Mungas, and Ramon Diaz-Arrastia for help with data collection as part of the EXAMINER executive function battery validation study.
GLOSSARY
ADAlzheimer disease
ASantisaccade
BASbedside antisaccade
BNTBoston Naming Test
CATSComprehensive Affect Testing System
CDRClinical Dementia Rating
CDR-SBClinical Dementia Rating–sum of boxes
EXAMINERExecutive Abilities: Methods and Instruments for Neurobehavioral Evaluation and Research
FrSBeFrontal Systems Behavior Scale
FTDfrontotemporal dementia
HDHuntington disease
ITIintertrial interval
MCImild cognitive impairment
MMSEMini-Mental State Examination
MSmultiple sclerosis
NEnormal elder
PDParkinson disease
PSprosaccade
PSPprogressive supranuclear palsy
RSMSRevised Self-Monitoring Scale
TBItraumatic brain injury
UCSFUniversity of California, San Francisco
VOSPVisual Object Spatial Perception

Footnotes
Editorial, page 1806
See page 1816
Supplemental data at www.neurology.org
AUTHOR CONTRIBUTIONS
Dr. Hellmuth, Mr. Mirsky, Dr. Matlin, Mr. Jafari, Dr. Garbutt, Ms. Widmeyer, Ms. Berhel, and Ms. Sinha performed assessments and analyzed data. Dr. Hellmuth, Mr. Mirsky, Dr. Heuer, Dr. Miller, Dr. Kramer, and Dr. Boxer contributed to writing and revising the manuscript. Dr. Kramer and Dr. Boxer designed the study.
DISCLOSURE
Dr. Hellmuth, Mr. Mirsky, Dr. Heuer, Dr. Matlin, Mr. Jafari, Dr. Garbutt, Ms. Widmeyer, Ms. Berhel, and Ms. Sinha report no disclosures. Dr. Miller serves on a scientific advisory board for the Alzheimer's Disease Clinical Study; serves as an Editor for Neurocase and as an Associate Editor of ADAD; receives royalties from the publication of Behavioral Neurology of Dementia (Cambridge, 2009), Handbook of Neurology (Elsevier, 2009), and The Human Frontal Lobes (Guilford, 2008); serves as a consultant for Lundbeck Inc., Elan Corporation, and Allon Therapeutics, Inc.; serves on speakers' bureaus for Novartis and Pfizer Inc.; and receives research support from Novartis and the NIH (NIA P50 AG23501 [PI] and NIA P01 AG19724[PI]) and the State of California Alzheimer's Center. Dr. Kramer receives royalties from Pearson for the publication of commercially available neuropsychological tests. He receives research support from the NIH (2R01AG022983, 1R01AG032289, HHSN271200623661C). Dr. Boxer has been a consultant for Accera, Bristol Myers Squibb, Genentech, Medivation, Phloronol, Registrat-Mapi, and TauRx. He has received research funding from Allon Therapeutics, Avid, Elan, Forest, Genentech, Janssen, Medivation, and Pfizer. He is funded by NIH grants R01AG038791 [PI], R01AG031278 [PI], the Alzheimer's Drug Discovery Foundation, CurePSP, the Hellman Family Foundation, and the Tau Research Consortium. Go to Neurology.org for full disclosures.
1. Everling S, Fischer B. The antisaccade: a review of basic research and clinical studies. Neuropsychologia 1998;36:885–899. [PubMed]
2. Hallet PE. Primary and secondary saccades to goals defined by instructions. Vision Res 1978;18:1279–1296. [PubMed]
3. Munoz DP, Everling S. Look away: the anti-saccade task and the voluntary control of eye movement. Nat Rev Neurosci 2004;5:218–228. [PubMed]
4. Mirsky J, Heuer HW, Jafari A, et al. Anti-saccade performance predicts executive function and brain structure in normal elders. Cogn Behav Neurol 2011;24:50–58. [PubMed]
5. Radant AD, Claypoole K, Wingerson DK, Cowley DS, Roy-Byrne PP. Relationships between neuropsychological and oculomotor measures in schizophrenia patients and normal controls. Biol Psychiatry 1997;42:797–805. [PubMed]
6. Hutton SB, Huddy V, Barnes TR, et al. The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia. Biol Psychiatry 2004;56:553–559. [PubMed]
7. Zanelli J, MacCabe J, Toulopoulou T, Walshe M, McDonald C, Murray R. Neuropsychological correlates of eye movement abnormalities in schizophrenic patients and their unaffected relatives. Psychiatry Res 2009;168:193–197. [PubMed]
8. Broerse A, Holthausen EA, van den Bosch RJ, den Boer JA. Does frontal normality exist in schizophrenia? A saccadic eye movement study. Psychiatry Res 2001;103:167–178. [PubMed]
9. Golding CV, Danchaivijitr C, Hodgson TL, Tabrizi SJ, Kennard C. Identification of an oculomotor biomarker of preclinical Huntington disease. Neurology 2006;67:485–487. [PubMed]
10. Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006;67:394–399. [PubMed]
11. Meyniel C, Rivaud-Pechoux S, Damier P, Gaymard B. Saccade impairments in patients with fronto-temporal dementia. J Neurol Neurosurg Psychiatry 2005;76:1581–1584. [PMC free article] [PubMed]
12. Boxer AL, Garbutt S, Rankin KP, et al. Medial versus lateral frontal lobe contributions to voluntary saccade control as revealed by the study of patients with frontal lobe degeneration. J Neurosci 2006;26:6354–6363. [PMC free article] [PubMed]
13. Garbutt S, Matlin A, Hellmuth J, et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease. Brain 2008;131:1268–1281. [PubMed]
14. Currie J, Ramsden B, McArthur C, Maruff P. Validation of a clinical antisaccadic eye movement test in the assessment of dementia. Arch Neurol 1991;48:644–648. [PubMed]
15. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801. [PubMed]
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414. [PubMed]
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944. [PubMed]
18. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554. [PubMed]
19. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9. [PubMed]
20. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54(suppl 5):S15–S19. [PubMed]
21. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127. [PubMed]
22. Albanese A. Diagnostic criteria for Parkinson's disease. Neurol Sci 2003;24(suppl 1):S23–S26. [PubMed]
23. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198. [PubMed]
24. Warrington EK, James M. The Visual Object and Space Perception Battery. Bury St Edmunds: Thames Valley Test Company; 1991.
25. Kaplan E, Goodglass H, Wintraub S. The Boston Naming Test. Philadelphia: Lea and Febiger; 1983.
26. Kramer JH, Jurik J, Sha SJ, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 2003;16:211–218. [PubMed]
27. Delis DC, Kaplan EB, Kramer JH. The Delis-Kaplan Executive Function System. San Antonio, TX: The Psychological Corporation; 2001.
28. Wechsler D. Wechsler Adult Intelligence Scale, third ed San Antonio, TX: The Psychological Corporation; 1997.
29. Eriksen BA, Eriksen CW. Effects of noise letters upon the identification of a target letter in a non-search task. Percept Psychophys 1974;16:143–149.
30. Lennox RD, Wolfe RN. Revision of the self-monitoring scale. J Pers Soc Psychol 1984;46:1349–1364. [PubMed]
31. McDonald S, Flanagan S, Rollins J, Kinch J. TASIT: a new clinical tool for assessing social perception after traumatic brain injury. J Head Trauma Rehabil 2003;18:219–238. [PubMed]
32. Malloy P, Grace J. A review of rating scales for measuring behavior change due to frontal systems damage. Cogn Behav Neurol 2005;18:18–27. [PubMed]
33. Shafiq-Antonacci R, Maruff P, Masters C, Currie J. Spectrum of saccade system function in Alzheimer disease. Arch Neurol 2003;60:1272–1278. [PubMed]
34. Hodgson T, Chamberlain M, Parris B, et al. The role of the ventrolateral frontal cortex in inhibitory oculomotor control. Brain 2007;130:1525–1537. [PubMed]
35. Ettinger U, Kumari V, Chitnis XA, et al. Volumetric neural correlates of antisaccade eye movements in first-episode psychosis. Am J Psychiatry 2004;161:1918–1921. [PubMed]
36. Ettinger U, Antonova E, Crawford TJ, et al. Structural neural correlates of prosaccade and antisaccade eye movements in healthy humans. Neuroimage 2005;24:487–494. [PubMed]
37. Levy DL, Mendell NR, Holzman PS. The antisaccade task and neuropsychological tests of prefrontal cortical integrity in schizophrenia: empirical findings and interpretative considerations. World Psychiatry 2004;3:32–40. [PubMed]
38. Dorris MC, Munoz DP. A neural correlate for the gap effect on saccadic reaction times in monkey. J Neurophysiol 1995;73:2558–2562. [PubMed]
39. Fischer B, Biscaldi M, Gezeck S. On the development of voluntary and reflexive components in human saccade generation. Brain Res 1997;754:285–297. [PubMed]
40. Radant AD, Dobie DJ, Calkins ME, et al. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res 2007;89:320–329. [PubMed]
Articles from Neurology are provided here courtesy of
American Academy of Neurology